title: Established and novel biomarkers in ST-elevation myocardial infarction.
abstract: Cardiac biomarkers assist in the diagnosis of and risk stratification in acute coronary syndromes. In ST-elevation myocardial infarction (STEMI), rapid diagnosis and initiation of reperfusion via primary percutaneous coronary intervention or fibrinolysis is often based on the clinical history and presenting ECG, but measurement of biomarkers in the early and/or late phases of STEMI may allow the selection of patients who are at increased or decreased risk of subsequent complications. Although the measurement of only three biomarkers (troponin, natriuretic peptides and C-reactive protein) are currently included in practice guidelines, more than 20 other novel cardiac biomarkers have been proposed to provide improved risk stratification after a STEMI.
authors.affiliation: Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
authors.forename: Jonathan W
authors.initials: JW
authors.lastname: Waks
authors.forename: Benjamin M
authors.initials: BM
authors.lastname: Scirica
mesh_terms: D015415:Biomarkers / Q000097:blood; D004562:Electrocardiography; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis*; D018570:Risk Assessment
chemical_list: D015415:Biomarkers